ePrints

Inhibition of poly(ADP-ribose) polymerase in cancer

Lookup NU author(s): Professor Ruth Plummer

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Inhibition of the DNA repair enzyme poly(ADP-ribose) polymerase-1 (PARP-1) has been extensively investigated in the pre-clinical setting as a strategy for chemo- or radio-potentiation. Recent evidence has suggested that PARP inhibitors might be active as single agents in certain rare inherited cancers that carry DNA repair defects. As a result, potent PARP-1 inhibitors have in the past three years entered early clinical trials in cancer patients, and the final results of these trials are eagerly awaited. © 2006 Elsevier Ltd. All rights reserved.

Publication metadata

Author(s): Plummer ER

Publication type: Review

Publication status: Published

Journal: Current Opinion in Pharmacology

Year: 2006

Volume: 6

Issue: 4

Pages: 364-368

Print publication date: 01/08/2006

ISSN (print): 1471-4892

ISSN (electronic):

URL: http://dx.doi.org/10.1016/j.coph.2006.02.004

DOI: 10.1016/j.coph.2006.02.004

Share